cyrilzakka/clinical-trials huggingface dataset:
Study on Nation-wide Health Care Quality Information Openness and Transparency Mechanism Establishment

Research objectives To provide people with sufficient information regarding health care and to improve its quality, this research endeavors to discuss the establishment of a health care information openness and transparency mechanism within the framework of the National Health Insurance system. This research also evaluates whether the transparency of health care quality information makes care givers provide better quality. Meanwhile, when appropriate information and quality index are presented to patients, patients shall have more knowledge about what they are dealing with, hence less misunderstanding between hospitals and patients would occur.

Research Methods

1. To revise indicators based on international trends, related literature and the need of people.
2. To present 50 sets of quality indicator statistically on the website, and provide updated information about the first 10 sets.
3. To analyze and explain the outcome and purposes of the indicator to the public.
4. To estimate the possible trend for the coming year, and provide adaptive strategy.
5. To promote the website, and hold workshops in all six regions of Taiwan.
6. To make the website linked to the top 5 most populated official and unofficial websites.
7. To respond to questions on the forum of the website daily, and maintain the system, update the website regularly.
8. To complete the acceptability survey on health care institutions and people.


Eligibility Criteria:
Inclusion Criteria:

* Outpatient ; healthy subjects patients

Exclusion Criteria:

* The plan excluded child / children and other minors who were the target respondents, mainly to investigate the medical information for public acceptance of the site, child / children is not suitable, so as to adults as the main investigation.
Early Feasibility of the Velocity™ Percutaneous PAVF System

An early feasibility study of the the initial safety and efficacy of the Velocity Percutaneous Arterio-Venous Fistula (pAVF) System when used to percutaneously create an arteriovenous fistula in patients with ESRD requiring hemodialysis vascular access.


Eligibility Criteria:
Inclusion Criteria:

* Age 18 years or older
* Diagnosed with ESRD and currently on hemodialysis for less than 12 months using a central venous catheter for access
* Eligible for a native surgical brachiocephalic arteriovenous fistula following assessment by the principal investigator and study sponsor
* Cubital perforating vein diameter of \> 2.5 mm and length \> 10.0 mm
* Proximal radial artery diameter ≥ 2.0 mm
* Patient is free of clinically significant conditions or illness within 30 days prior to the AV fistula that may compromise the procedure
* Willing and competent to give written informed consent

Exclusion Criteria:

* Distance between Proximal Radial Artery and Cubital Perforating vein \> 3mm
* Ipsilateral arm systolic blood pressure \< 110 mmHg
* Known central venous stenosis or central vein narrowing \> 50% ipsilateral to the study extremity
* Any obstruction of venous outflow from device implant site to the axillary vein
* Patients with occlusion of the ulnar or radial artery at any level or an abnormal Allen's test
* Any previous dialysis vascular access procedures in the study extremity
* History of steal syndrome (hand ischemia) from a previous hemodialysis vascular access of the non-study extremity which required intervention or access abandonment
* Upper extremity venous occlusion(s) and/or vessel abnormality(ies) of the study extremity that precludes endovascular AVF creation as determined by principal investigator or study sponsor
* Evidence of active systemic infections on day of the procedure or infection at the access site within the past 7 days
* History or evidence of severe cardiac disease (NYHA Functional Class III or IV), myocardial infarction within six months prior to study entry, ventricular tachyarrhythmias requiring continuing treatment, or unstable angina
* Currently being treated with another investigational device or drug
* Known adverse effects to sedation and/or anesthesia which cannot be adequately pre-medicated
* Uncontrolled or poorly controlled diabetes defined as a HbA1C \> 10%
* Hypercoagulable condition, bleeding diathesis or coagulation disorder
* Receiving anti-coagulant therapy that cannot be safely held in the peri-procedural period
* Edema of the upper arm of the study extremity
* Scheduled kidney transplant within 6 months of enrollment
* Peripheral white blood cell count \< 1.5 K/mm3 or platelet count \< 75,000 cells/mm3
* Current diagnosis of carcinoma (defined as in remission \< 1 year)
* Pregnant or currently breast feeding
* History of substance abuse or anticipated to be non- compliant with medical care or study requirements based on investigator judgment
* Allergies to NiTi alloy or any of the components of the Velocity Implant or Delivery System
* Written informed consent not obtainable
Radiomics Assess of Bevacizumab Plus Chemo in Colorectal Cancer Liver Metastases

Colorectal carcinoma with liver metastasis is one of the major problems bothering physicians worldwide. Bevacizumab combined with chemotherapy is the standard treatment recommended by several guidelines. Despite the high cost, a certain portion of patients couldn't benefit from this therapy. This study is aiming to find out the specific type of patients who would respond to bevacizumab by Radiomics approach, and evaluate the prediction value of this imaging model with clinical and genetic factors.


Eligibility Criteria:
Inclusion Criteria:

1. Colorectal carcinoma confirmed by pathological result.
2. Liver metastasis confirmed by imaging studies.
3. Treatment of bevacizumab combined with chemotherapy chosen by MDT team.
4. ECOG: 0-2.
5. Normal laboratory studies including liver\\renal\\bone marrow functions.
6. Expected lifespan more than 3 months.

Exclusion Criteria:

1. Previous treatment of colorectal cancer with liver metastasis.
2. Diagnosed with other malignancies.
3. Couldn't finish the trial due to several reasons such as allergy to chemotherapy drugs\\pregnancy or lactation\\chronic heart disease\\unable to sustain further treatment.
Clinical Trial to Evaluate the Efficacy and Safety of DA-2811 When Added to Ongoing Metformin Monotherapy in Patients with Type 2 Diabetes Who Have Inadequate Glycemic Control

This study is a multicenter, double-blind, active-controlled, randomized, parallel, phase IV clinical trial to evaluate the efficacy and safety of DA-2811 when added to ongoing metformin monotherapy in patients with type 2 diabetes who have inadequate glycemic control


Eligibility Criteria:
Inclusion Criteria:

* Subjects with 7.0%≤HbA1c≤10.0% at screening
* Subjects treated with 1,000mg/day or higher dose of metformin for at least 8 weeks prior to screening
* Subjects with 18.5kg/m2≤BMI≤40kg/m2 at screening
* Subject who is willing and able to provide informed consent indicating that they understand the purpose and procedures required for the study

Exclusion Criteria:

* Subjects with fasting plasma glucose≥240mg/dL at screening
* Patients with type 1 diabetes mellitus, secondary diabetes mellitus or gestational diabetes mellitus
* Subject with ALT and AST 3 times or higher than upper normal range
* Subject with history of myocardial infarction, cerebral infarction within 3 months prior to screening
Evaluating Modulation Effects of Burst Stimulation Patterns Using SEEG

The study aims to evaluate modulation effects of burst stimulation patterns via SEEG.

Our research group plans to conduct a study on patients with drug-resistant epilepsy who have SEEG electrodes implanted. The study will evaluate and compare the modulation effect of single-pulse electrical stimulation, paired electrical stimulation, stepwise electrical stimulation, and burst electrical stimulation via direct electrical stimulation using SEEG. The goal is to explore the focal and network modulation effect of distinct stimulation paradigms during the resting state and post-seizure state.

Eligibility Criteria:
Inclusion Criteria:

* Drug-resistant focal epilepsy
* Justified SEEG exploration in the context of presurgical assessment of epilepsy
* Subjects will be a part of the epilepsy-monitoring unit for long-term SEEG recordings and analysis
* Written non-opposition to study participation

Exclusion Criteria:

* Pregnant women (Contraindication to SEEG exploration)
* Psychiatric disorders
* History of psychotic disorders
* History of cranial trauma serious (according to the classification), previous or evolutionary other neurological pathology
* Subjects that experience surgical complications during the implant procedure will be excluded from the study
Innovative Training Program for Elderly in Need of Care

The goal of this randomized controlled study was to examine the effects of a 8 weeks innovative training regime (stochastic resonance whole-body vibration \[SR-WBV\] and virtual virtual games \[VG\]) in the skilling up phase on physical performance, cognition and falls in elderly in need of care population.

Sensorimotor and strength exercise are methods to increase strength \& power in the field of geriatrics. The question that arise what exercises are best suited to and most effective for elderly in need of care individuals. Such populations are advised first to enter a "skilling up program" before more traditional forms of training exercises are implemented.

Goals in the skilling up phase: improvement in neuromuscular control, postural control and strengthening of large muscle groups of the lower extremity.

The aim of the study in the skilling up phase:

Study the effect on physical performance Study the effects on muscle strength. Study the effects on cognition. The participants will be recruited in Canton Zurich, Swizerland and will be randomly allocated to an intervention group or sham group

Eligibility Criteria:
Inclusion Criteria:

* RAI (Resident Assessment Instrument) \>0
* live in canton Zurich
* in terms of training load be resistant.

Exclusion Criteria:

* acut joint disease, acut thrombosis, acute fractures, acute infections, acute tissue damage, or acute

  * surgical scars
  * seniors with prosthesis.
  * alcoholic
  * acute joint disease, activated osteoarthritis, rheumatoid arthritis, acute lower limb
  * acute inflammation or infection tumors
  * fresh surgical wounds
  * severe migraine
  * epilepsy acute severe pain
A Study to Evaluate the Effectiveness and Safety of 3 Doses of Paliperidone Palmitate in Treating Subjects With Schizophrenia

The purpose of this study is to evaluate the effectiveness and safety of 3 doses of paliperidone palmitate in treating subjects with schizophrenia.

This is a randomized, double-blind, placebo-controlled, parallel-group, multicenter, dose-response study of patients who have a Diagnostic and Statistical Manual of Mental Disorders, 4th edition (DSM IV) diagnosis of schizophrenia. The duration of the study is approximately 14 weeks, including a screening period of 1 week and a 13-week double-blind treatment period. Efficacy and safety will be evaluated periodically throughout the study. Samples for pharmacokinetic evaluation will be collected at designated time points, and a blood sample will be collected at baseline (before the start of double-blind treatment) for an optional pharmacogenomics (genetics) analysis. The hypothesis is that the 3 fixed doses of paliperidone are each more efficacious than placebo in treating subjects with schizophrenia. The effectiveness is measured primarily by the change in the Positive and Negative Syndrome Scale for Schizophrenia (PANSS), and secondarily, by the investigator's Clinical Global Impression of Severity (CGI-S) and by the investigator's evaluation of the patient on a Personal and Social Performance (PSP) Scale. Four injections of paliperidone palmitate 50, 100, or 150 milligrams equivalent administered in the gluteal muscle (buttocks). Injections will be given on Days 1, 8, 36, and 64 of the double-blind treatment period of the study.

Eligibility Criteria:
Inclusion Criteria:

* A DSM-IV diagnosis of schizophrenia (disorganized, catatonic, paranoid, residual, or undifferentiated type) for at least 1 year before the screening evaluation
* a total PANSS score of 70 to 120 at screening and baseline (pre-treatment) evaluations
* a body mass index (BMI \[weight (kilograms)\]/\[height (meters)\]²) of more than 17.0 kg/m²

Exclusion Criteria:

* A primary active DSM-IV Axis I diagnosis other than schizophrenia
* a decrease of 25% or more in the total PANSS score between screening and baseline evaluations
* a DSM-IV diagnosis of active substance dependence within 3 months of screening evaluation
* a history of treatment resistance as defined by failure to respond to 2 adequate trials of different antipsychotic medications
* a woman who is pregnant, breast-feeding, or planning to become pregnant during the study period.
The Effect of Tyrosine Kinase Receptor Axl on Dialysis Prognosis in Chronic Hemodialysis Patients

The purpose of this study is to evaluate whether tyrosine kinase receptor Axl affects the dialysis prognosis in chronic hemodialysis patients

It is reported that hemodialysis (HD) patients often develop chronic systemic inflammatoion, and increased inflammatory activity is associated with vascular access failure, cardiovascular disease and death in HD patients. The interaction of Axl and its ligand Gas6 plays an important role in modulating immune response, inhabiting toll-like receptor (TLR) signaling and suppressing inflammatory cytokines production. Thus, we want to investigate the relationship between tyrosine kinase receptor Axl and the dialysis prognosis in HD patients in three-years follow-up.

Eligibility Criteria:
Inclusion Criteria:

* hemodialysis for more than 6 months

Exclusion Criteria:

* patients who received warfarin therapy;
* patients with chronic infectious disease or acute infection;
* patients with hemodialysis inadequacy;
* the age of patients is older than 65 years or younger than 18 years.
* patients who can not sign an informed consent or disagree to follow up
Professional and Ethical Challenges of Social Media Usage in Providing Healthcare Services During the Period of 19 Covid Pandemics;

integrating social media into medicine has obvious potential to improve patient care and trust in the profession, in part by meeting patients "where they are," i.e., online, at the same time carries a greater risk in terms of legal, ethical, and professional aspects. Therefore, physicians and medical students using social media should pay attention to the ethical sensitivity in their relationships with patients .it also raises a number of ethical issues including protecting patient and physician privacy; setting appropriate online boundaries; and delineating personal and professional identities among others during covid 19 pandemics


Eligibility Criteria:
Inclusion Criteria:

1. adult aged 18 years to 60 years
2. medical personel graduated from egyptian faculty of medicine.
3. non medical personel live in egypt

Exclusion Criteria:

1. personel less than 18 years old .
2. medical personel not graduated from egyptian faculty of medicine.
3. non medical personel live outside egypt
A Modified Phase I Study of NGR-hTNF in Advanced Solid Tumors

The main objective of the trial is to explore the safety and biological activity of NGR-hTNF. The safety will be established by clinical and laboratory assessment. The biological activity will be evaluated by DCE-MRI with contrast media.

This is a modified phase I Single arm, open, non randomized trial of NGR-hTNF in advanced solid tumors for the definition of an optimal biological

Eligibility Criteria:
Inclusion Criteria:

* Patients \>18 years old with proven advanced solid tumors not amenable to any clinical improvement by current standard treatments. Tumors recognized to be highly vascularized (e.g. renal, colon thyroid and head and neck cancers), will be included.
* ECOG Performance status 0 - 2
* Patients may have had prior therapy providing the following conditions are met:

  * Chemo, radio, hormonal or immunotherapy: wash-out period of 28 days
  * Surgery: wash-out period of 14 days
* Adequate baseline bone marrow, hepatic and renal function, defined as follows:
* Neutrophils \> 1.5 x 10\^9/L and platelets \> 100 x 10\^9/L
* Bilirubin \< 1.5 x ULN
* AST and/or ALT \< 2.5 x ULN in absence of liver metastases
* AST and/or ALT \< 5 x ULN in presence of liver metastases
* Serum creatinine \< 1.5 x ULN
* Absence of any conditions in which hypervolemia and its consequences (e.g. increased stroke volume, elevated blood pressure) or haemodilution could represent a risk for the patient (reference appendix "Technical data sheet human albumin")
* Normal cardiac function and absence of uncontrolled hypertension
* Patients must give written informed consent to participate in the study

Exclusion Criteria:

* Concurrent anticancer therapy
* Patients may not receive any other investigational agents while on study
* Clinical signs of CNS involvement
* Patients with active or uncontrolled systemic disease/infections or with serious illness or medical conditions, which is incompatible with the protocol
* Known hypersensitivity/allergic reaction to human albumin preparations or to any of the excipients
* Any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol
* Pregnancy or lactation. Patients - both males and females - with reproductive potential (i.e. menopausal for less than 1-year and not surgically sterilized) must practice effective contraceptive measures throughout the study. Women of childbearing potential must provide a negative pregnancy test (serum or urine) within 14 days prior to registration.
Late Feasibility Study to Evaluate Safety and Efficacy of AWAK PD Device in Subjects With ESKD.

The goal of this late feasibility clinical trial is to evaluate the safety and effectiveness of the Automated Wearable Artificial Kidney (AWAK) peritoneal dialysis (PD) device in subjects with end-stage kidney disease. The main questions it aims to answer are:

* the success of AWAK PD therapies when used in a home-setting
* the safety and effectiveness of the AWAK PD system

Participants will:

* be titrated to find a suitable AWAK PD prescription
* be trained on how to use the AWAK PD system independently
* use the AWAK PD system at home for at least 7 days


Eligibility Criteria:
Inclusion Criteria:

1. Written informed consent to participate in the study.
2. Male or female ≥22 years of age.
3. Treated with PD for at least 3 months before Screening.
4. Has weekly Kt/Vurea (renal + peritoneal) ≥1.7
5. No acute peritonitis, catheter infection, exit site, or subcutaneous tunnel infection within 3 months before Screening.

Exclusion Criteria:

1. Severe comorbidity or poor general physical/mental health that, in the opinion of the investigator, will not allow the subject to be a good investigation candidate
2. Recent (within the previous 6 months) history of major cardiovascular events (e.g., stroke, acute myocardial infarction).
3. Diagnosed with New York Heart Association (NYHA) Class III or Class IV heart failure.
4. Poorly controlled diabetes mellitus as defined by hemoglobin A1c \>9.0% during Screening
5. Subject has a current abdominal hernia.
6. Subject has an active infection requiring systemic antibiotics or antifungal therapy.
7. Active infection of hepatitis B and C, or HIV infection at any time.
Study to Assess Efficacy and Safety of Inecalcitol in Imatinib-Treated Residual Chronic Myeloid Leukaemia: INIM Study

To assess the efficacy of inecalcitol in combination with imatinib in CML patients with molecular residual disease on imatinib monotherapy.

To determine:

* Duration of response
* Progression free survival
* Proportion of responders 2 years after discontinuation of inecalcitol
* Duration of response after discontinuation of inecalcitol and imatinib
* Bone remodelling effect
* Safety of inecalcitol in combination with imatinib
* Quality of Life

Eligibility Criteria:
Inclusion Criteria:

* Men or women aged of at least 18 years at the time of informed consent signature;
* Patients have signed written informed consent;
* ECOG performance status \< 2;
* Patients with Philadelphia chromosome positive chronic phase CML and M BCR-ABL transcript positivity (e13a2 or e14a2);
* Treatment with imatinib for more than 2 years (a history of treatment with interferon is tolerated);
* Patient in complete cytogenetic response with BCR-ABL/ABL status between 0.1% International Scale (IS) and 0.01% IS and no BCR-ABL checkpoint in the last six months better than Molecular Response MR4 ( i.e. BCR-ABL ratio \< 0.01% IS);
* Women of child bearing potential have a negative pregnancy test prior to first dose and agree to practice effective contraception during the study;
* Fertile men agree to practice effective contraception during the study;
* Patients agree to comply with the study requirements and agree to come to the clinic for required study visits;
* Patients agree to follow medication restrictions during the study;

Exclusion Criteria:

* Expression of unusual BCR-ABL transcripts (other than e13a2 or e14a2);
* Pregnant or lactating women;
* Participating in another clinical trial with any investigative drug within 30 days prior to study enrolment(except for OPTIM imatinib);
* Treatment with interferon within the last 24 months;
* Imatinib dose modification within the last 3 months;
* Prior history of haematopoietic stem cell transplantation;
* Impaired renal function with creatinine clearance \< 30 ml/min/1.73m² according to the MDRD formula;
* Hypercalcemia (corrected with albuminemia);
* History of diseases known to be associated with calcium disorders: ongoing hyperparathyroidism, sarcoidosis....;
* Presence or history of symptomatic kidney stones in the last 5 years;
* Current use of drugs known to influence serum calcium (such as thiazide diuretics, teriparatide, calcitonin and multivitamin supplements containing \> 400 IU of vitamin D or calcium);
* Current use of digitalis;
* Current use of drugs which could influence bioavailability of inecalcitol (such as magnesium-containing antacids, bile-resin binders);
* Patients with a chronic condition which is not well controlled that, according to the investigator, would interfere with the completion of the study;
* Use of any other experimental drug, therapy or vitamin D supplementation within 30 days of first inecalcitol administration;
* Patients with a mental deficiency preventing proper understanding of trial protocol requirements;